Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity

OncoImmunology

Volumn 3, Issue 11, 2014, Pages e967146-1-e967146-4

  Castelli, Chiara ^a   Triebel, Frédéric ^b   Rivoltini, Licia ^a   Camisaschi, Chiara ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

IMP 321; lymphocyte activation gene 3 (LAG 3); melanoma; plasmacytoid dendritic cells (pDCs); psoriasis

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL TRIAL (TOPIC); GENE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION GENE 3; MOLECULARLY TARGETED THERAPY; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 84937072222     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.967146     Document Type: Article

References (10)

1. J.Tel, S.P.Sittig, R.A.Blom, L.J.Cruz, G.Schreibelt, C.G.Figdor, I.J.de Vries. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol 2013; 191:5005-12; PMID:24127556; http://dx.doi.org/10.4049/jimmunol.1300787
2. B.Reizis, A.Bunin, H.S.Ghosh, K.L.Lewis, V.Sisirak. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 2011; 29:163-83; PMID:21219184; http://dx.doi.org/10.1146/annurev-immunol-031210-101345
3. T.O.1.Jensen, H.Schmidt, H.J.Møller, F.Donskov, M.Høyer, P.Sjoegren, I.J.Christensen, T.Steiniche. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer. 2012;118:2476-85; PMID:21953023; http://dx.doi.org/10.1002/cncr.26511
4. C.Camisaschi, A.De Filippo, V.Beretta, B.Vergani, A.Villa, E.Vergani, M.Santinami, A.D.Cabras, F.Arienti, F.Triebel, Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol 2014; 134:1893-902; PMID:24441096; http://dx.doi.org/10.1038/jid.2014.29
5. M.Guha. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 2012; 11:503-5; PMID:22743965; http://dx.doi.org/10.1038/nrd3775
6. J.Matsuzaki, S.Gnjatic, P.Mhawech-Fauceglia, A.Beck, A.Miller, T.Tsuji, C.Eppolito, F.Qian, S.Lele, P.Shrikant, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107:7875-80; PMID:20385810; http://dx.doi.org/10.1073/pnas.1003345107
7. C.Camisaschi, C.Casati, F.Rini, M.Perego, A.De Filippo, F.Triebel, G.Parmiani, F.Belli, L.Rivoltini, C.Castelli. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010; 184:6545-51; PMID:20421648; http://dx.doi.org/10.4049/jimmunol.0903879
8. N.Gagliani, C.F.Magnani, S.Huber, M.E.Gianolini, M.Pala, P.Licona-Limon, B.Guo, D.R.Herbert, A.Bulfone, F.Trentini, Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013; 19:739-46; PMID:23624599; http://dx.doi.org/10.1038/nm.3179
9. O.Boyman, C.Conrad, G.Tonel, M.Gilliet, F.O.Nestle. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol 2007; 28:51-7; PMID:17197238; http://dx.doi.org/10.1016/j.it.2006.12.005
10. C.Casati, C.Camisaschi, F.Rini, F.Arienti, L.Rivoltini, F.Triebel, G.Parmiani, C.Castelli. Soluble human LAG-3 molcule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res 2006; 66:4450-60; PMID:16618772; http://dx.doi.org/10.1158/0008-5472.CAN-05-2728